RGDXQ — Response Genetics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Response Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2010 December 31st | 2011 December 31st | 2012 December 31st | 2013 December 31st | 2014 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 21.3 | 22.6 | 18.7 | 19.8 | 16.7 |
| Cost of Revenue | |||||
| Gross Profit | 10.8 | 10.9 | 8.32 | 9.35 | 6.71 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 26.2 | 28.3 | 26.4 | 27.7 | 29.7 |
| Operating Profit | -4.88 | -5.68 | -7.66 | -7.95 | -13 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.67 | -5.7 | -7.76 | -8.02 | -13.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.67 | -5.7 | -7.76 | -8.02 | -13.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.67 | -5.7 | -7.76 | -8.02 | -13.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -4.67 | -5.7 | -7.76 | -8.02 | -13.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.263 | -0.298 | -0.29 | -0.3 | -0.353 |
| Dividends per Share |